Showing results (1-10 of 80) with videos related to
Sort By:
Pageof 8
Frontiers in Pharmacology|March 14, 2022
Physiological Considerations for Modeling in vivo Antibody-Target InteractionsTyler Dunlap, Yanguang CaoPharmaceutical Research|September 2, 2022
Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?Timothy Qi, Tyler Dunlap, Yanguang CaoElife|July 25, 2023
Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistanceCan Liu, Jiawei Zhou, Stephan Kudlacek, et al.Cancers|August 26, 2023
Decoding the Complexity of Immune-Cancer Cell Interactions: Empowering the Future of Cancer ImmunotherapyKaitlyn Maffuid, Yanguang CaoMedicine|December 22, 2019
Plasma miR-200c-3p, miR-100-5p, and miR-1826 serve as potential diagnostic biomarkers for knee osteoarthritis: Randomized controlled trialsZhen Lai, Yanguang CaoJournal of Pharmacokinetics and Pharmacodynamics|September 2, 2017
Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxelHua He, Yanguang CaoInternational Journal of Molecular Sciences|April 3, 2021
In Translation: FcRn across the Therapeutic SpectrumTimothy Qi, Yanguang CaoCPT: Pharmacometrics & Systems Pharmacology|December 22, 2022
Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non-small cell lung cancerTimothy Qi, Yanguang CaoMathematical Biosciences and Engineering : MBE|February 2, 2021
Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodesEric Salgado, Yanguang CaoPharmaceutics|April 3, 2021
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future DirectionsYu Tang, Yanguang CaoPageof 8